Podcasts about Soldato

Il servizio militare è volontario per le donne nella maggior parte dei paesi, ma la coscrizione è in aumentohttps://www.radiobullets.com/notiziari/8-aprile-2025-notizie-donne-mondo-podcast/

Torna la Direzione Gara più squalificata dei circoli per anziani, con l'analisi del Gran Premio di Cina, tra norme violate, sedili eiettati e soluzioni aerodinamiche altamente discutibili.Da oggi anche in video (circa)!

Il conducente della possente vettura americana notte avrebbe tentato la fuga a piedi, ma le ferite riportate nello schianto lo hanno fatto stramazzare a terra. Ieri alle 5 il soldato non aveva rispettato l'altolà di una Volante della Questura, procedendo pericolosamente ad alta velocità tra viale San Lazzaro e via Genova, fino allo schianto.

Inizia l'anno nuovo con il piede giusto e acquista il piano biennale di NordVPN per iniziare a proteggerti online, otterrai 4 Mesi Extra e come al solito 30 giorni di soddisfatti o rimborsati Vai su https://nordvpn.com/dentrolastoria Il nostro canale Youtube: https://www.youtube.com/channel/UC1vziHBEp0gc9gAhR740fCw Il Nostro SITO: https://www.dentrolastoria.net/ Sostieni DENTRO LA STORIA su Patreon: https://www.patreon.com/dentrolastoria Abbonati al canale: https://www.youtube.com/channel/UC1vziHBEp0gc9gAhR740fCw/join Il nostro store in Amazon: https://www.amazon.it/shop/dentrolastoria Sostienici su PayPal: https://paypal.me/infinitybeat La sera del 24 gennaio 1972 due pescatori di gamberetti di Guam, nel Pacifico, vengono assaliti nel buio da una figura minuta e oscura. In pochi minuti i due pescatori riescono ad aver ragione del loro assalitore scoprendo che si tratta di un 57enne giapponese magro, smunto, che indossa abiti di fortuna. Dopo avergli offerto una zuppa calda, i pescatori lo consegnano alle autorità mediche americane che scoprono finalmente la verità: quell'uomo emerso dalla giungla è Shoichi Yokoi, uno dei soldati imperiali scomparsi che per 28 anni si era rifiutato di arrendersi al corso della Storia sopravvivendo con mezzi di fortuna nell'ostinata venerazione del suo imperatore. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dopo i successi, Morandi deve affrontare la censura e il conseguente allontanamento dalla scena musicale.

Se anche la tua crush, immaginandosi sola in un bosco, ha detto di preferire la compagnia di un orso alla tua, prima di mettere seriamente in discussione il tuo savoir-faire, sappi che quel trend era già virale nel 1942. E sì, già allora le donne preferivano gli orsi ai maschi etero cis…See omnystudio.com/listener for privacy information.

È tornato a trovarci Emiliano Coltorti, storica voce di personaggi come Pennywise, Luigi, Soldato d’Inverno, Dahmer e tantissimi altri. Nella puntata di oggi vedremo quanto effettivamente impatta lo studio nella formazione di un doppiatore, e quanto invece possedere una voce “particolare”. Cercheremo anche di capire quanto è reale l’ipotesi che l’intelligenza artificiale prenda il posto dei doppiatori in carne ed ossa.See omnystudio.com/listener for privacy information.

Con l'aiuto di Chiara Bustreo analizziamo e svisceriamo la sofferta vittoria contro la Georgia, provando a non demoralizzarci per la supersfida agli All Blacks di sabato sera.Spazio anche a dibattiti sul giocatore più forte al mondo, qualche consiglio per il fantarugby e dei pronostici forse un po' azzardati._________________________⠀⠀⠀⠀⠀⠀Canale Ovale è prodotto da Vita Sportiva, realtà editoriale di approfondimento sportivo nelle diverse vesti digitali, nonché una rete di podcast.L'obiettivo di VS è contribuire alla creazione e alla diffusione di una vera Cultura Sportiva.Per questo i contenuti sono aperti a tutti, sempre gratuiti. Se tu vuoi continuare ad usufruirne gratis, ne siamo fieri. Ma se vuoi sentirti parte della realizzazione di quest'obiettivo, allora invia un contributo a Vita Sportiva. Ci aiuterai a resistere, rendendo sostenibile il nostro lavoro e ripagando le spese che il blog, i social e i podcast richiedono. Grazie!Sostienici ora qui: www.gofundme.com/f/sostieni-vita-sportiva⠀⠀⠀⠀

Il gelato piace a tutti, e ok, ma durante la seconda guerra mondiale era anche molto utile a tenere alto il morale dei soldati americani. Purtroppo però non tutti riuscivano a consumarlo per motivi logistici, così la Air Force decise di sviluppare un metodo rudimentale per produrre gelato ad alta quota durante i bombardamenti.See omnystudio.com/listener for privacy information.

“Fai quello che ami e non lavorerai neanche un giorno della tua vita”. Il protagonista della puntata di oggi ha preso questo aforisma un po’ troppo lettera considerando che la sua grande passione era la guerra. Ma per citare un altro grande aforisma “se devi fare qualcosa, tanto vale farla bene”, e infatti il nostro eroe è scampato così tante volte alla morte da essere soprannominato “il soldato che non si può uccidere”.See omnystudio.com/listener for privacy information.

Host Dr. Davide Soldato and Dr. Shelia Garland discuss the JCO article "Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato. I am a Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO author Dr. Sheila Garland. She's a Professor of Psychology and Oncology at Memorial University, and she's the director at the Sleep, Health, and Wellness Lab and Senior Scientist at the Beatrice Hunter Cancer Research Institute. Dr. Garland will be discussing the article titled, “Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors.” Thank you for speaking with us, Dr. Garland.  Dr. Sheila Garland: Thank you so much for having me. Dr. Davide Soldato: So, Dr. Garland, you designed a study that relied on cognitive behavioral therapy to treat insomnia, and then you assessed whether improvement in insomnia would be associated with an improvement in cancer related cognitive impairment. So I wanted to ask if you could give us a little bit of context and explain the rationale between these studies. So how common are these symptoms among cancer survivors, and why do we think that improving insomnia would also improve cognitive function?  Dr. Sheila Garland: Yeah, thank you very much. That's a really, really good question. And so cognitive behavior therapy for insomnia has been used to successfully treat insomnia in cancer survivors for quite some time. I think JCO was one of the first publishers to really demonstrate the potency of this intervention to improve insomnia. But as we know, patients will often present not just with insomnia, but insomnia comorbid with pain, fatigue, and very commonly cognitive impairment. If we take a look at the experimental research in sleep, we know that sleep quality and quantity is associated with very important cognitive functions. And so we've had clear sleep deprivation studies where if you're not able to successfully get sufficient quality or quantity of sleep, you're going to have impairments in attention and concentration and memory. So it really makes sense that if we're able to improve sleep in cancer survivors, that we're also able to address maybe some of the other concerns that they would have related to sleep. So this is an important clinical question for the patient's quality of life, but I also think it has important system implications where if we're looking at like resources and efficiency of allocating those resources, if we have an intervention that can treat multiple problems, that means that we can more effectively address lots of symptoms and use fewer resources in doing so. So that was the thought in designing this trial. Dr. Davide Soldato: Thank you very much. That was very, very clear. So you spoke about the intervention that you implemented in the clinical trial. So I was wondering if you could give us a little bit of context. How long was the intervention? What were the main points addressed? Because you said that, in the end, we already have some data regarding cognitive behavioral therapy for treating insomnia. So I was wondering, did you personalize in any way, the program or the intervention to fit more to the cancer survivors population?  Dr. Sheila Garland: Yeah. So it is based on a protocol that has been well researched and has a great deal of evidence of efficacy. But we delivered this intervention over a course of seven weeks. So individuals had individual sessions with a trained therapist, and those sessions lasted about an hour and were over roughly about two months or so. Seven sessions over two months. And because they were delivered individually, there was some adaptation based on the clients' presenting problems. So while there's sort of a standard protocol, if the client is also presented with levels of fatigue or pain or anxiety or depression, the therapist was able to integrate those concepts into the therapy as well. There was nothing for cognitive impairment. So there was no additional intervention for cognitive impairment at all. We weren't doing any memory training or anything like that. So it was strictly the sleep and other symptoms looking at the impact of improving that on not only your perception of your cognitive abilities, but also on performance on a number of neuropsychological test measures. Dr. Davide Soldato: So thank you very much for the detail. And I think that it's very interesting what you said, that the personalization of the intervention would also allow to treat some other symptoms that are distressing for cancer survivors. Like, for example, you mentioned fatigue or anxiety or depression. And I think that this goes back to the first point that you made about the intervention. So being able to treat different symptoms all at one in one single intervention, I think that that is a very intelligent use of resources and also to promote and implement, potentially some interventions that are beneficial for survivors of cancer on different domains and potentially different symptoms. So, going to the results a little bit, what did you observe regarding specifically insomnia with the intervention that you delivered? Dr. Sheila Garland: Yeah, so, of course, we wanted to make sure that we were effective in targeting the primary outcome of what the trial was supposed to do, which was we were supposed to treat effectively, treat insomnia, and then determine whether treating that insomnia was related to improvements in cognition. So we were expecting that the intervention itself was going to be successful at improving insomnia, and we were. So we were able to not only demonstrate a statistically, but also a clinically meaningful improvement in insomnia severity. Usually that's measured by a change of about 8.4 on a measure called the insomnia severity index. And the change that we were able to produce was over 11 points. So it was clearly over the clinically meaningful change threshold. Dr. Davide Soldato: Going back a little bit to the design of the study, this was a randomized clinical trial. And how did you allocate the participants of the study into which arms? And can you guide us a little bit in the study design?  Dr. Sheila Garland: Yes. A lot of thought went into the study design. We ultimately decided on having a waitlist randomized controlled trial, and this was because there is no other intervention for insomnia that has comparable efficacy. And we felt it would be unethical to not give people the standard treatment that we know works to treat insomnia. So that's where having them wait for a period of time and then receive the treatment was ultimately what we decided on. Overall, we were able to recruit 132 participants, and those were randomized into either receiving treatment immediately or receiving treatment after a two month waiting period. Dr. Davide Soldato: So you mentioned that the intervention was actually very effective for treating insomnia. You reported an improvement in the insomnia severity index of almost 11 points. And as you mentioned, this is both clinically meaningful and it was also statistically significant. Did you see any improvement also on cognitive function, and how did you measure this outcome? Was it self reported, or did you also have some objective measure to see, for example, working memory or some other type of cognitive function? Dr. Sheila Garland: Yeah. Also, a lot of thought went into choosing the primary outcome for this. And there's people who have argued compellingly that self reported cognitive function should be the primary target because we know, based on past research, that objective and subjective ratings of cognitive performance do not always correlate well with each other. And taking a very patient oriented approach, we wanted to make sure that we prioritized the patient's perception of their own function. We used one of the subscales of the functional assessment of cancer treatment cognition scale. So it was the Perceived Cognitive Impairment subscale that was what we used as our primary, but we also reported the two other subscales, which was the Perceived Cognitive Abilities and the Impact of Cognition on Quality of Life. We were able to not only discover that there were clinically significant improvements on all three of those subscales, but actually translated into, again, the clinically meaningful change threshold that's been established for the perceived cognitive impairment subscale is, I think it's around, like 5.9 points. So, using that cutoff, 75% of the participants in the trial reported clinically meaningful improvements in their perceived cognitive impairments, compared to just 43% of those participants in the wait list group. And we looked not only at the immediate intervention effects, but also on whether they were durable. So we had follow up assessments of both three months and six months after completing treatment, and the effects on insomnia, as well as the cognitive dimensions, they were maintained.  Dr. Davide Soldato: Thank you very much for this last remark, because I think that one of the worries I would say that we have when implementing this type of behavioral intervention is that in the end, the change that we produce and the behavioral change that we produce might be effective in the immediate time after completing the intervention. But frequently we sort of see the loss of this benefit that we produce with the intervention at later time points. And I think that this is very important that you also looked at the benefit that was maintained over time for the three and six months after the end of the intervention. And it's true that before we add some data regarding other types of behavioral intervention, for example, for weight loss or some other symptoms and other toxicity that we frequently target with this type of intervention, I was wondering, do you think that it's something specific to cognitive behavioral therapy and the specific symptoms that you were treating, so insomnia, that in the end, produced a durable and meaningful benefit over time?  Dr. Sheila Garland: So I do think that there's something really specific about this type of intervention. With insomnia, you're really changing the person's fear of not sleeping, and you're giving them tools to be able to both prevent the reocurrence of insomnia and also if the reocurrence should happen, they know what to do then to address it themselves. I was very curious about the impact that it might have long term. I actually wasn't sure whether it would have an effect immediately, considering that people do accumulate kind of a sleep debt after having insufficient sleep for a period of time. So I didn't know whether we would see anything immediately. I thought maybe we would need the long term follow ups to see some of the effect. But I guess maybe not surprisingly, at the end of the trial, thinking about when somebody has a good night's sleep, they're feeling the effects even the next day. Dr. Davide Soldato: Thank you. That was very insightful. Regarding the duration of the intervention, because in the end, this was very short, because it was just seven sessions weekly, and usually also when we design or implement this kind of behavioral intervention, we frequently go for a longer period of time where the patient is subjected to this type of behavioral intervention. Frequently, we see around three, six months of intervention. And so I think it's really amazing the effect that you had on this specific symptom with such a short intervention. So I think that that is also something that speaks to the possibility of further implementing this type of intervention and this type of program for symptom control.   And going back a little bit to what was one of the main questions of the trial that you designed and the results of the article that you published, did you observe a mediating effect of the improvement of insomnia on the cognitive function? So, you said that insomnia improved, and so improved also your primary outcome, which was the scale of the FACT-Cog questionnaire. But did you see whether this improvement in cognitive function was really related and associated to the improvement that you observed in insomnia? Dr. Sheila Garland: Yeah. So that was a very, very important question. We needed to first demonstrate that there was a relationship between the intervention and insomnia, and then there was a relationship between insomnia and cognition. And then we did some mediation analyses subsequent to determining both of those, and we found that the change in insomnia was a full mediator of the change in cognition. So we were able to say that it's not just time or it wasn't related to something else, that improving sleep did have this direct effect on the improvement that patients reported in their cognitive impairment.  Dr. Davide Soldato: We spoke a lot about the subjective improvement in cognitive performance. But you said that you also evaluated some specific and objective scale with, for example, I imagine some neuropsychological tests. Did you also observe some improvement for those specific tests, and did you observe the same amount of benefit or the same improvement, we could say, between the subjective and the objective weight of measuring cognitive function?  Dr. Sheila Garland: I think that's where the outcomes become a little less clear. So, we did measure performance based cognition at all of the time points, and we were very careful in selecting these measures. So we followed the guidance provided by the International Task Force on Cognition and Cancer. They had some very specific recommendations about how and what measures we use. So we made sure to use measures that were able to be repeated, so that had multiple forms, that had very identifiable ways to indicate improvements. So we used the Hopkins Verbal Learning Test to measure word recall, both immediately and delayed. We used measures to look at verbal fluency and working memory. Overall, we had six different specific aspects of cognition that we were looking at, immediate word recall, delayed word recall, word retention, verbal fluency, word recognition, and working memory. Some of those presented with a different pattern of change overall. So a little bit trickier to interpret than the person's perception of their own cognition. Dr. Davide Soldato: That's very interesting because it's important to have this kind of objective assessment. But in the end, what we are really trying to target is a symptom that is distressing for cancer survivors. I'm not even sure that sometimes we need all of this detail, or at least that even if these outcomes that are more objectively measured, we do not observe the same amount of benefits. Still, if we are able to produce an improvement in the symptoms and the perception that the survivor or the individual or the patient, whoever we are trying to help in that specific moment and for those specific symptoms, reports an improvement, I think that is already very important. And I totally share the patient oriented approach that you followed in the study.  Going back a little bit to the population, because I think that this speaks a little bit also to potential avenues for further research. You included a population of cancer survivors who completed treatment at least six months before being enrolled in the trial. And relating to the population, I had two questions. So the first one is, do you think that you would have the same kind of results, so the same benefit, also among a population of patients who's in active treatment? And then the second one is a little bit more speculation, but do you think that we will arrive, or do you envision research where we kind of deliver this type of intervention in sort of a preventative way? So if we would be able to identify those patients who might later develop these types of symptoms, could we use this type of intervention sooner? So can we prevent these symptoms even before they appear? And could this be potentially associated also in a less symptoms developed over time and less need to treat these symptoms when they become more severe?  Dr. Sheila Garland: Those are two very, very good questions. The first one is regarding the population. You're right. These people were at least six months out of treatment, and we wanted to make sure that if there was any temporary disruption, that would have maybe been stabilized over that. But most of the people in this trial, and I will mention that we didn't focus on any specific cancer type or site. So this was really a heterogeneous group of cancer survivors, both male and female. The most prevalent diagnosis that we had was breast. But some of these people who were enrolled in the trial had advanced cancer, and as long as their cancer treatment, their regimen was stable, they were eligible to participate in the trial. So I think that's a very important point. If somebody is on a very intensive round of chemotherapy, it can be tricky to implement some of the more aggressive behavioral changes that can come with some of these insomnia treatments, because their level of wellness just isn't there. So during active treatment it can be challenging, but it is definitely not impossible. We would just tweak things a little bit to accommodate their physical well being at that time.  To your next question, though, this is where I think we really need to be going. Just like they've done in the area of, like, physical activity, trying to really strengthen people prior to treatment is the way to go. Because some of my other research looked at symptoms prospectively from the time of diagnosis over the first year, and it's roughly about half of people, at least, this was in my work with women with breast cancer, about half of women with breast cancer come into treatment with clinically significant sleep problems. So, a proportion of those people just continue to have sleep problems or even get worse after it. So there's definitely a role for that, sort of like rehabilitation, not only for maybe physical fitness to try and ward off fatigue, but also getting their sleep on track. I think people are really focused, especially in that early time, about like, “I want to eat right, I want to exercise,” but I say it as many times as I possibly can, that you're not going to make healthy food choices, and you're not going to be getting out there and working out if you're not getting sufficient sleep. So we really need to have sleep there as the foundation and what supports all of those other healthy lifestyle behaviors that people are trying to change. Dr. Davide Soldato: So sort of comprehensive intervention for people undergoing treatment where we kind of identify symptoms that are already there at the beginning, and we deliver some sort of intervention that can target a lot of those symptoms, maybe not all of them, but maybe improving also the way that treatment is perceived or the toxicity that they might develop over treatment. Dr. Sheila Garland: And that's what I think. I think that if you're taking people who are already coming into treatment, that are looking after their health in ways that they can, they may be able to tolerate more aggressive treatments, they might be able to complete more rounds of chemotherapy, just getting them strong, going into treatment that way.  Dr. Davide Soldato: Also still focusing on that very patient oriented perspective that I think it's very important in general for oncologists and also for patients. I think that you were very wise in choosing an intervention that could be also delivered virtually, and this was one of the bases of the intervention. And regarding also the way the intervention was delivered, I had a question regarding the fact that this was actually an intervention that was delivered by professionals. But we also have some, maybe initial evidence, that suggests that some of this cognitive behavioral therapy can also be experienced, or at least the benefits can be obtained by the patients, even when it's self directed. So programs where patients are not actually interacting with a professional, but they are just following these types of programs. So do you think that there is room for both of those? And maybe should we suggest this type of self directed programs for all patients or all survivors and then just refer only those with a more significant or important symptom severity for the intervention with professionals? And this, I think, also goes to the discussion that we had at the very beginning about allocation of resources and ability also to tailor these types of interventions to the needs of different individuals. Dr. Sheila Garland: I think that's really important to consider when looking at what's available for patients. They did a survey in the US of NCI Cancer Centers where they looked at the availability of CBT-I, and it was very low. I think around 20% or so of NCI Comprehensive Cancer Centers had the ability to refer to in-house CBT-I. If we had sort of a stepped care model like you're talking about, we may be able to more appropriately allocate people to the level of care that they need. A line of my research now is going into a specific app delivered cognitive behavior therapy for insomnia tailored to cancer survivors. And so looking at that very point, not everybody needs a provider, but I think that a self help manual or an app is also not going to work for everybody. So you're not going to completely take out the person. And depending on the complexity of the situation that the patient finds themselves in, they may really need that provider to consider all of the other factors. They might need it to encourage adherence or address maybe some of the barriers that would be getting in the way. So having different levels of care and being able to match people not only to the level of care, but also maybe by their preference. So, “I'd like to use an app.” Great, we've got an app for you. Or “I'd like to see somebody.” And I think matching it to people's preferences automatically encourages or enhances their engagement and their motivation to complete because they're getting what their preference would be. Dr. Davide Soldato: And I think that at least if we could use a little bit more of these types of apps or tools or whatever we have out there, maybe we could increase at least that 20%. For example, if only 20% of NCI Cancer Centers, which are already places where care is delivered, probably with a higher attention to these types of symptoms for survivors compared, for example, to community hospitals or to smaller private clinics. So if we could at least have sort of a base and then refer only those that maybe have a higher need for a provider directed therapy or intervention, that maybe would also improve outcomes for a larger part of the population of survivors.   And one other thing that I wanted to ask you is, do you think, in your experience, because this was not really in the trial that you designed, but do you think that we also need cultural adaptation of these types of programs? Meaning, do we need to diversify based, for example, on ethnicity or level of education or, I don't know, just the background that the patient is experiencing? Dr. Sheila Garland: Yeah, very, very good points. There are some studies currently being conducted out of the United States that have looked at cultural adaptations of CBT-I specifically. So there was a trial looking at CBT-I for African American women survivors of breast cancer, and also the Latinx population as well. From the results of those trials, it didn't necessarily improve the effects of intervention, but it improved the engagement, so people were less likely to drop out. So it wasn't always the content. It was how the content was presented. So people were able to visually see themselves more, they were able to relate more to the content in just the way it was presented, which made them go, “Oh, okay. This is why I should be here.” And I think that that's part of the argument that I used for sort of adapting the cognitive behavior therapy for insomnia treatment that's being used in the general population, specifically to people who have had cancer, because people want to know, “All right. You know what? Is this safe for me to do? Will this work for me to do? How do I also do this when I have cancer related fatigue, or how do I do this when I also have pain?” So they want to know that, “Alright. This is right for me.” That's probably, again, relating more to getting people and keeping people engaged with the treatment, maybe even convincing them to do it to begin with, talking about getting buy-in from important leaders in their community to say, “This is something that I would recommend or I would endorse.” And those sort of community level endorsements maybe are just breaking down barriers to get people willing to engage with an evidence based treatment.  Dr. Davide Soldato: And I think especially with cognitive behavioral therapy, because I think that when we propose drugs for treating symptoms or, I don't know, intervention for losing weight or to be more physically engaged, well, the latter that I mentioned might be also a little bit more complicated, depending on the cultural context. But drugs are very easy to accept for the patients in most cases. But I think that cognitive behavioral therapy also has some type of cultural resistance, maybe among some of our patients and cancer survivors.  Dr. Sheila Garland: And I would also include oncologists in there as well. So, some of the treatment providers are not even exactly sure why would talking about this help. So I think separating it out, it's not just I'm going to talk about my sleep, it's that I'm going to engage with my sleep differently and breaking down maybe some of the stigma that, just because we're referring you to cognitive behavior therapy doesn't mean your problems are all in your head, but it means that there's ways that you can think about your sleep and ways that you can behave differently, which will reduce the things that are getting in the way of your sleep functioning the way that it should normally. I think when I talk to patients, and also when I do training with providers, I talk about how we can condition our bed to be associated with things other than sleep. So if we repeatedly snack in front of the tv, even though we've just had supper maybe a half an hour before, if we go and sit down in that chair that we always snack in, we're not hungry, but we find ourselves reaching for something to eat. The same thing can happen at night, where if you repeatedly pair your bed with things other than sleep, if you're thinking in bed, if you're planning, if you're worrying, if you're ruminating, if you know you're doing anything, if you're on your screen or you're watching tv or you're doing anything that's arousal producing, people can find that they're so tired, they're nodding off on the couch. They go up to bed, and all of a sudden, bang, they're wide awake and their mind is turning and they're thinking and they're like, “Why is this happening to me? I was just tired. I was so tired.” People with insomnia can relate to that very easily. That, “Oh, okay. So there's this conditioned association between my bed and wakefulness. How do I get rid of that?” That's where what we think and what we do around our sleep, we can change to be able to make our bed someplace that is strongly associated with sleep and not all of those other activities.  Dr. Davide Soldato: Thank you for the remarks on oncologists and sometimes our resistance to accept this type of intervention. I think that this also speaks to the merit of the Journal of Clinical Oncology, which publishes high level evidence also on symptom management, and these types of interventions that are, in the end, effective for our patients.  So I think that this concludes our interview for today. Thank you again, Dr. Garland for joining us.  Dr. Sheila Garland: Thank you Dr. Soldato. Dr. Davide Soldato: Dr. Garland, we appreciate you sharing more on your JCO article titled, “Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors.” If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.      

Film da Oscar per questa settimana di “Che film guardo stasera?”. Per tutto il mese di agosto, Betty Senatore ripropone alcune delle migliori puntate del podcast.See omnystudio.com/listener for privacy information.

Von der Leyen mantiene il timone della Commissione europea..ma aggiusterà la rotta sul Green Deal?Carlo Stagnaro ne parla con Simone Mori, docente Luiss e senior advisor Arthur D. Little, in una nuova intervista LeoniFilesPreferisci seguire su YouTube?

Giovanni Di Lorenzo è stato il peggiore in campo nella sfida con la Spagna. L'attuale capitano del Napoli vive un momento difficile, amplificato da una serie di scelte cervellotiche fuori dal campo.See omnystudio.com/listener for privacy information.

In ogni libro, film, canzone, serie tv, opera d’arte, c’è sempre la scintilla di un’idea. Winston, come l’eroe di 1984 di George Orwell, vuole trovarla e raccontarla, anche solo per uno spunto, per cinque giorni alla settimana per circa quattro minuti. Dal lunedì al venerdì. Un podcast di Pierluigi Battista per HuffPost.See omnystudio.com/listener for privacy information.

Produzione e Sound Design - Matteo D'AlessandroCanale Youtube: https://www.youtube.com/channel/UC-Idufifk1hamoBzkZngr1wGruppo Facebook : https://www.facebook.com/groups/624562554783646/Gruppo Whatsapp: https://whatsapp.com/channel/0029VaD1eQk8vd1WyYUzH01cIl nostro Instagram: https://www.instagram.com/bibliotecadialessandria/?hl=it

Un soldato statunitense si è dato fuoco fuori dall'ambasciata israeliana a Washington: dopo aver fatto partire una diretta Twitch, ha detto di non voler essere più "complice del genocidio" a cui gli Stati Uniti stanno contribuendo in Palestina. Andrea De Cesco, esperta di podcast, ci consiglia l'ultimo podcast prodotto e narrato da Pablo Trincia: Sangue Loro – Mandato a uccidere, sulla storia in parte dimenticata degli attacchi stragisti degli anni ‘80 in Italia Rassegna stampa: Aaron Bushnell, è morto il soldato statunitense che si è dato fuoco per protestare contro la guerra a Gaza, Luigi Mastrodonato Per proteggere gli animali allevati, ispiriamoci a questi risultati del 2023

Ridley Scott dirige Demi Moore in questo film d'azione del 1997. Jordan (detta Jane) O'Neil, già membro della Marina, viene selezionata come unica donna per prendere parte al rigido addestramento dei Navy Seals. Per portare a termine la sua missione, però, dovrà affrontare discriminazioni e pregiudizi in un ambiente ostile al genere femminile.See omnystudio.com/listener for privacy information.

In this episode of JCO Article Insights, host Dr. Soldato discussed with Dr. Knikman and Dr. Cats the findings of a study that assesses the influence of fluoropyrimidine dosing based on DYPD genotype on both progression-free and overall survival. The article, featured in the December edition of JCO, presents groundbreaking and reassuring data. Furthermore, it highlights emerging research challenges aimed at refining the prescription practices of one of the most widely utilized chemotherapy agents, striking a delicate balance between safety and efficacy. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Davide Soldato: Welcome to this JCO Article Insights episode for the December issues of the Journal of Clinical Oncology. This is Davide Soldato, and today I will have the pleasure of interviewing Dr. Knikman and Dr. Cats, respectively first and corresponding authors of the manuscript titled "Survival of Patients with Cancer with the DPYD Variant Alleles and Dose Individualized Fluoropyrimidine Therapy: A Matched-Pair Analysis."  Dr. Knikman is a clinical pharmacologist and assistant professor at the UMC Utrecht, while Dr. Cats is a gastroenterologist specializing in gastrointestinal oncology at the NKI in the Netherlands.  Welcome, Dr. Knikman and Dr. Cats, and thank you for accepting our invitation today.  Dr. Annemieke Cats: Thank you so much for the invitation. Davide Soldato: So I just wanted to start by discussing the manuscript that you published. But before delving into the results of the manuscript that was published in the JCO, I just wanted to ask if you could give a brief overview of the DPD polymorphism and explain a little its relevance in the clinical practice.  Dr. Annemieke Cats: The DPD polymorphism is very important in the metabolism of fluoropyrimidines. Fluoropyrimidines have been in practice for over seven decades now in the world and more than 2 million people received fluoropyrimidines in the beginning of this millennium. The indications for fluoropyrimidines have only been extended since then, so a lot of people are receiving this fluoropyrimidines. But with the good side of that there's also another side and that is that there are a lot of side effects encountered by this chemotherapeutic drug. In the 1990s, it became clear that DPD was a key enzyme in the metabolism of fluoropyrimidines. Dr. Jonathan Knikman: To better understand the toxicity associated which fluoropyrimidines are accompanied by, we have to take a closer look at the metabolism of fluoropyrimidines, and more specifically at the key metabolic enzyme which is dehydropyrimidin dehydrogenase, DPD in short. This enzyme breaks down the main active metabolite into inactive metabolites because 5-fluorouracil is the main active metabolite which is metabolized into inactive metabolites. However, if this enzyme does not function properly, this could lead to higher exposures of the active metabolites and subsequently more toxicity. This can be caused by mutations in the gene encoding for the DPD enzyme, which is the DPYD gene, and single nucleotide polymorphisms, so mutations in this gene can lead to less functional DPYD enzymes, subsequently can lead to more toxicity.  Davide Soldato: So basically, patients that are harboring these SNPs in the gene encoding for the enzyme have a higher risk of toxicities. I think what is really important about the manuscript you published is that, apart from looking at the toxicities, side effects and pseudo profile among these patients who harbor these SNPs you also wanted to check whether this was associated with some reduction or at least with inferior clinical outcomes. The endpoints you selected were progression-free survival and overall survival. But I was really interested, and I think our readers and listeners would be interested in understanding a little bit the methods of the study. What was the cohort of patients that was selected? Was this a cohort composed only of patients with gastrointestinal malignancy or also different types of malignancies? And in this second case, if you included the patients with different types of malignancies, did you have any methods to be sure that there was not any differences among these patients at the very beginning? So basically, how you handled all the confounding factors that could potentially impact the analysis of clinical outcomes. Dr. Annemieke Cats: To start your question, we have to go back to a previous study we performed, which was a prospective, multicenter study we performed in the Netherlands in 17 centers in which 1100 patients that had an indication for fluoropyrimidine therapy were included. In these 1100 patients, there were about 85 patients that were heterozygous carriers of a DPYD variant. What we did, we compared these two groups with each other, but before the DPYD carriers started, they had a reduced dose. The *2A variant carriers and the *13 carriers, they received a 50% dose, and the 1236 and 2846 they received a 75% dose. Those patients, a large amount of them consisted of patient with colorectal cancer, about 60%. And also breast cancer patients consist for a large amount of this group, it was about 20%. And then the rest were esophageal and gastric cancer mostly, and there was a group consisting of rare tumors as well like anal cancer.  The comparisons showed that toxicity in the variant carriers was higher in the wild-type patients that received 100% dose. So despite those reductions, toxicity was higher in the carriers. But when we compared the variant carriers with historical controls, we saw that, especially for *2A, there was a large reduction of toxicity to a lesser amount. This was also the case for the 2846 variant carrier. But to a much lesser extent, there was a reduction in the 1236 carriers which worried us and this was the basis for a Clinical Pharmacogenetics Implementation Consortium (CPIC) to give a recommendation for starting for all these variant carriers with a 50% dose when treatment with fluoropyrimidine was indicated. Davide Soldato: Thank you very much for the clarification. So basically, you started from one previous prospective study that was composed of a mix of different cancer types. And then in the study that you now published in the Journal of Clinical Oncology, you also added an additional part of patients who were carriers of this variants. I imagine that there was some variability between patients who were carrying the variants and those were not carrying a variant. So I wanted to understand a little bit, did you perform a matched analysis or did you try to be sure that there was not any confounding factors that could impact the results? Dr. Jonathan Knikman: Yes, we performed an exploratory retrospective matched-pair analysis and we used a matched-pair analysis to select patients which are comparable between the DPYD variant carriers and the DPYD wild-type patients to ensure that on the most important factors, they were comparable and outcome was also comparable. In this matched-pair analysis, we compared progression-free survival and overall survival between DPYD variant carriers treated with the reduced dose and DPYD wild-type patients treated with the full dose. We matched these patients on five matching variables which were primary tumor type, stage of cancer, age within a range of plus or minus 10 years, sex, and treatment regimen to ensure the these patients as comparable as possible.   Davide Soldato: And so now, moving on a little bit to the results, what were the results in brief regarding progression-free survival and overall survival for patients who were harboring a variant in the DPYD gene and those who were wild-type for this gene? Dr. Annemieke Cats:The results of our study showed that there was no significant difference in progression-free survival and overall survival between the DPYD variant carriers pooled as one group, treated with the reduced dose, compared to wild-type patients treated with the full dose. This suggests that DPYD-guided dosing can be performed safely without compromising treatment effectiveness. However, when we take a closer look at the individual variants, our study showed that progression-free survival and overall survival were not negatively impacted by DPYD-guided dosing in the 2846 and the DPYD *2A variant groups. However, in the group of 1236 variant carriers, we did find a significant difference in progression-free survival with a hazard ratio of 1.43, indicating that progression-free survival  was shorter compared to the matched wild-type patients treated with the full dose. However, no difference was found in overall survival.   So based on results on this study, we can conclude that DPYD-guided dosing can be used while treating patients with fluoropyrimidines without compromising effectiveness and improving safety. However, when patients do not experience toxicity or experience minimal toxicity, it is important to escalate the dose guided by toxicity to ensure maximum exposure to the treatment.  Davide Soldato: Thank you very much. That was a very comprehensive overview of the results. I was really wondering regarding the variants in the 1236. So the one that you said was associated with a shorter progression-free survival. At the very beginning, Dr. Cats very well explained that in the first prospective trial that was done, among these patients, toxicity was still higher or they experienced more severe toxicities, even with a 25% dose reduction compared to what was planned. So I was wondering if you could speculate a little bit. Do you think that this reduction in the progression-free survival might potentially be associated with these higher rates of severe adverse events, and that maybe this has created a little bit of a gap in the adherence to chemotherapy? Dr. Annemieke Cats: We looked into the mean dose that the 1236 variant carriers received, and this was about 75% of the dosage. So the dosage was what the protocol prescribed for the study. And also the number of cycles did not differ from the wild-type patients. So, I think the patients did not stop earlier with their treatment than was intended to. What we did see however is that in the whole group, only 10% of the variant carriers had some kind of dose modification, which could be both an increase of the dose or a reduction of the dose. So, there were only a few patients where the dose was modified. We know that the 1236 variant carriers are a very heterogeneous group. DPD enzyme activity also shows a wide range, ranging from normal to very low dose even we described a patient with a homozygous 1236 mutation. And we would expect that there would be no DPD enzyme activity, but there was still some activity in this patient.  Davide Soldato: That's a very good insight on this particular topic. So, just related to the conversation that we were just having, do you think that in general, for all DPD variants, and in particular, as we discussed, for the 1236, do you think that genotyping is sufficient for now to understand which is the right dose for these patients, to balance toxicities and to obtain the best clinical outcomes? Or do you think that we need more sophisticated or more integrated types of monitoring? Should we, for example, in the 1236, look more carefully at pharmacokinetics and so understand if these patients can receive higher doses because maybe, as you were saying, the activity of the enzyme is really higher than what we are expecting based on the genotype? Do you envision something like this happening in the future, or do you consider it as a potential line of research on this topic?  Dr. Jonathan Knikman: It's a very interesting question, and it's something we've thought about a lot. At the moment, I think genotyping is the way to go and is the most robust and most validated method currently available with fluoropyrimidines. And I think it's a bit of both. Currently, as mentioned, I would recommend DPYD genotyping, and also in the 1236 variant carriers, as we have seen in previous studies, that toxicity is still increased even while administering 75% dose instead of a full dose. So we see that there's still more toxicity. However, our study also shows that progression-free survival is shorter compared to wild-type patients. So, it's quite a complex situation as we still have more toxicity, but the progression-free survival is also shorter, and that's where we would advise the dose escalation part. So, I think it's a combination of genotyping and escalating the dose when possible, if there is no toxicity or limited toxicity, to ensure maximum exposure and to minimize the effect on progression-free survival while still trying to reduce toxicity. Dr. Annemieke Cats: This is a very important question because we do not completely understand why toxicity is higher in the 1236 with a 25% dose reduction that may compromise progression-free survival. So we have to look in closer detail, and currently we are looking in closer detail to what do we have for a pharmacokinetic analysis, that you mentioned. What about DPD activity, enzyme activity? Can you titrate on that? And I think for now, it still stands that we should start with a 50% dose, but with the possible effectiveness of the dose in mind, you should go with an early titration, and I would say something about 25%. Although having said that, I have no data to underline this. And if you have the possibility to go for DPD enzyme activity in addition to genotyping, that would also help you to titrate doses on that. And that's where we stand now. But we need to know why these 1236 variant carriers have such a large range in activity and toxicity. Davide Soldato: I also think, and I can ask you if you agree with me, that this analysis is really very important because I think it's one of the first reports regarding the analysis, specifically of progression-free survival and overall survival based on variants of DPD. But at the same time, I think that we also have to underline for our listeners that this was still a retrospective and exploratory analysis. So it's true that you observed this association with shorter progression-free survival. But still, I think that we will need also more core studies to validate these findings and to be really sure and also to perform additional analysis as to what the mechanism is as you were saying. I don't know if you agree on this limitation of the study, despite its importance in regarding clinical outcomes. Dr. Annemieke Cats: We certainly agree with you that we have to keep in mind that it is an exploratory, retrospective analysis. Having said that, a randomized controlled trial certainly has some difficulties in it as well. Nowadays, it is not feasible to give patients with a DPYD variant a full dose. In 2018, there was a lawsuit in Oregon, and now recently in Ontario, Canada. There's also a lot of rumor in the news because of patients getting a full dose while having a DPYD variant. So the lethality of the toxicity in some variant carriers makes it not ethical to perform a randomized controlled trial. So we have to look for different designs that reflect real-world data and learn more about the genotype and also in different ethnicities. It is also very important because what we have studied considers the white population mostly and that's also a direction that future research should go to.  Davide Soldato: Thank you very much. That was very insightful, especially the last part regarding ethnicity and the possibility that also these variants might be different according to that.  So I think that the main message that we should pass is that when prescribing fluoropyrimidines, genotyping of DPD is fundamental because toxicities among patients harboring these variants can be severe and can also be lethal. You performed this retrospective exploratory analysis that provided us with overall reassuring data. There is still more research to be done, especially for the 1236 variant. So I think that that probably is our bottom line and main message for our listeners.  And I just had one final question because in the manuscript that you published, you had localized, locally advanced, and also metastatic cancer that were all grouped together. Do you think that an additional line of research would be to specifically look at how these impactful outcomes only in the locally advanced and localized cancer compared, for example, with the metastatic? Dr. Annemieke Cats: You raised a very good point because there is a lot of variety within this study, and now you're mentioning locally advanced, local, or metastatic cancer. It's also within the cancer types. We studied different cancer types as well to reach a large amount of patients. It would be good to have a more homogeneous population that you can derive your conclusions from. So, I think that would certainly help us in the future, and we should look into whether we could do this together because before we had such a large population, we would need several countries to work together.  Davide Soldato: Yeah, you're totally right. Thank you very much for underlining that last point.  Thank you very much, Dr. Knikman and Dr. Cats, for being here with us today and for explaining to us and our listeners the results of your research. That concludes this episode of JCO Article Insights. We discussed the manuscript titled "Survival of Patients with Cancer with DPD Variant Alleles and Dose of Individualized Fluoropyrimidine Therapy: A Matched Pair Analysis." This is Davide Soldato, your host. Thank you for your attention, and stay tuned for the next episode.  The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Il padre e la madre si conobbero alla stazione. La storia rispolverata dal periodico inglese 'InTrieste'.

Un tuffo nel puro romanticismo con chi ne è la star mondiale indiscussa. Al BSMT è passato James Blunt. Nato a Tidworth, in Inghilterra, e appassionato di musica sin da bambino, James Blunt, subito dopo gli studi, decide di arruolarsi nell'esercito britannico. È solo nel 2002 che, una volta lasciato l'esercito, si dedica alla costruzione della sua carriera nel mondo della musica. Firmando il suo primo contratto discografico entra nella scena musicale internazionale e con canzoni come You're beautiful e Goodbye my lover conquista i cuori di tutto il mondo. Una chiacchierata in cui abbiamo scoperto anche il lato divertente e leggero della voce che ha fatto struggere milioni di adolescenti, e non, con le sue ballate malinconiche e romantiche. Al BSMT James Blunt si è raccontato completamente, partendo dall'arruolamento nell'esercito fino al nuovissimo progetto discografico Who We Used To Be, senza tralasciare i grandissimi successi che lo hanno reso una star internazionale. Buona visione! Learn more about your ad choices. Visit megaphone.fm/adchoices

In questa nuova fantastica favola nel traffico ritroviamo dei coraggiosi personaggi che abbiamo già avuto il piacere di conoscere nella favola 04 - L'aeroplanino delle verdure. In questo episodio scopriremo un nuovo amico della compagnia, l'impavido Carota Arancione! Riusciranno i nostri amici a salvarlo dal gelido frigorifero? Ascolta questa favola per scoprirlo! E tu? Qual'è la verdura che ti piace mangiare di più? Fammelo sapere con un messaggio vocale su Whatsapp al numero 353/4453010! GUARDA anche l'episodio su YOUTUBE! --- Send in a voice message: https://podcasters.spotify.com/pod/show/lorenzostivani/message

La capacitá di ascoltare é la piú importante premessa per iniziare un dialogo con l'altro, anche quando l'altro é apparentemente anni luce distante da noi. In questa guerra tra Israele e Hamas, il dibattito, anche qui da noi, si é subito polarizzato in due grandi fazioni che non si ascoltano. Abbiamo il dovere, in quanto Europei, di ascoltare tutto e tutti e trattenere ció che vale. In questa puntata di Ragazzacci abbiamo intervistato Michael: un ragazzo israeliano in attesa di essere chiamato al fronte. Learn more about your ad choices. Visit megaphone.fm/adchoices

Il soldato Travis King lascia la Corea del Nord e finisce in custodia statunitense. Il caso del giocatore del Napoli offeso su TikTok (dalla su stessa squadra). Scopri come sostenere Will iscrivendoti alla membership Learn more about your ad choices. Visit megaphone.fm/adchoices

Lo strano caso dei preti soldato

di Alessandro Luna | Tra gli argomenti di oggi Giorgetti al Meeting di Rimini, Salvini in difesa del generale Vannacci e il summit dei Brics Learn more about your ad choices. Visit megaphone.fm/adchoices

Zielinski rifiuta l'offerta dell'Arabia: dunque, c'è ancora qualcuno che resiste. Il pasticciaccio-Samardzic danneggia soprattutto il giocatore. Dopo le difficoltà di luglio, Lotito piazza un grande mercato: biancocelesti ad altezza scudetto?

La maternità surrogata come “reato universale”. Cosa sappiamo del soldato statunitense che ha varcato il confine della Corea del Nord Learn more about your ad choices. Visit megaphone.fm/adchoices

Compie esattamente 25 anni questo capolavoro di Steven Spielberg. E' il 6 giugno del 1944 e l'esercito americano si sta preparando allo sbarco in Normandia, per spezzare le ultime resistenze dei tedeschi. Quando lo sbarco, tra innumerevoli vittime, si chiude con successo, il capitano Miller riceve l'ordine di trovare il soldato Ryan che, rimasto l'ultimo superstite dopo la morte dei suoi tre fratelli su altri fronti di guerra, deve essere preso e rispedito a casa dalla madre. Miller sceglie un gruppo di soldati e parte per questa missione oltre le linee nemiche. Nel cast tra tutti Tom Hanks, Matt Damon, Giovanni Ribisi, Paul Giamatti.See omnystudio.com/listener for privacy information.

In this JCO Article Insights episode, Davide Soldato interviews Dr. Naqash  from University of Oklahoma. Dr. Naqash provides insight into the original article published in the July JCO issue: “Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium”. The interview offers a deep dive into the manuscript results on efficacy and safety of Immune Checkpoint Inhibitors in this specific population and offers insights on future research direction in this space. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Davide Soldato: Welcome to this JCO Article Insights episode for the July issues of JCO. This is Davide Soldato and today I will have the pleasure of interviewing Dr. Abdul Rafeh Naqash, the author of the manuscript titled "Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer: A Real World Report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International Consortium."  Dr. Naqash is an Assistant Professor of Hematology-Oncology at the University of Oklahoma and a Medical Oncologist working at the Stephenson Cancer Center. His research interests revolve around early-phase clinical trials in solid tumors, lung cancer, and the study of immunotherapy, biomarkers, and resistance.  Welcome, Dr. Naqash, and thank you for accepting our invitation today. Dr. Abdul Rafeh Naqash: Dr. Soldato, thanks so much for having me. I'm really excited to discuss this article with you today. Davide Soldato: So I just wanted to go a little bit over the manuscript with you. So basically, this is a retrospective multicenter study that was conducted across the US, Europe, and Australia by the CATCH-IT Consortium. And so the aim of the study was really to investigate the safety and the activity of immune checkpoint inhibitors among patients diagnosed with cancer and also living with HIV. The article examined two different cohorts, and I just wanted to start with a brief explanation of how the two cohorts were built so that our readers can get a little bit of understanding of what you did then. Dr. Abdul Rafeh Naqash: Sure. Before I take a deep dive into the cohorts, Dr. Soldato, I would definitely like to mention the premise and the background for this paper as to why we did what we did. And one of the primary reasons was that people living with HIV, historically, there have been very limited number of trials that have included these individuals. So it becomes a very important question from a disparity standpoint. And most often we end up, in the real world setting, we end up extrapolating data from clinical trials, but not necessarily know what is the outcome of these individuals in the real world setting.  So there have been some very important studies in the last three years or so in people with HIV as far as clinical trials with checkpoint inhibitors go, but most of those trials have been limited by the number of patients, number of people that have been part of those trials. So we wanted to understand it from a broad perspective, whether it is from a broad geographic perspective or from a heterogeneous patient population perspective, which is why we built this consortium called the CATCH-IT Consortium, which basically stands for Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International Consortium. And this required a lot of effort from a lot of different centers, including those in the US, Europe, and Australia, as you mentioned. And then we ended up having data worth around 400 plus patients, close to 400 patients or so. And then we wanted to look at obviously outcomes, whether it's related to a certain tumor such as lung cancer, which we did in this case, or a pan tumor assessment of toxicities and safeties.  So, to your question, the cohorts that we basically had, we had close to approximately 390 patients that we included in the safety analysis. So first we looked at the safety analysis, which was the entire cohort, and then out of those we excluded around 12 patients or so. Those were patients that were treated in the adjuvant setting. So in the metastatic advanced setting, we had close to 378 individuals that we assessed clinical outcomes for. So, response rates, progression-free survival, and overall survival. And then as far as a separate cohort, we looked at non-small cell lung cancer, which was the most commonly represented tumor type, with approximately 111 patients that had non-small cell lung cancer. We did exclude a certain proportion of those that were earlier stage, stage III.  So in the stage IV, basically we ended up matching in this separate cohort, around 60 odd patients or so of non-small cell lung cancer to 110 stage four, non-small cell lung cancers. So basically it was a one-to-two matching and we chose the same site. So if a site had, let's say, two people with HIV and lung cancer treatment checkpoint, we tried to match it to approximately four to five patients from the same site and we used some variables for matching so that we had some level of homogeneity between the HIV patient population and the non-HIV positive lung cancer individuals. So that's basically cohort A was around 370-something patients, tumor agnostic advanced metastatic setting. Cohort B was lung cancer individuals matched to non-HIV positive lung cancer treatment checkpoint inhibitors. Davide Soldato: Thank you very much. That was very clear. Just to go back to what you were saying before because I think that this is very interesting. You mentioned that patients living with HIV were mostly excluded from clinical trials and in the few that included them, there were some restrictive criteria in terms for example of CD4-positive cells in the blood. And so I was wondering if when you included the patients inside of this cohort, you also had this type of exclusion criteria or you chose a broader population to make the results more generalizable and applicable in clinical practice.  Dr. Abdul Rafeh Naqash: Right, a very important question. Thank you, Dr. Soldato. So yes, previous clinical trials have had some level of restrictions as far as the inclusion of these individuals, but in our study, this was a real-world study, basically, patients whoever presents to the clinic with a history of HIV, they were all included. So we did not restrict it to certain CD4 counts or viral loads because the important thing was we wanted to understand the ground situation of how these individuals do, irrespective of some of these limitations. As far as what we identified as baseline CD counts or HIV viral load positivity, we took three months before immune checkpoint initiation as a cut off so obviously there's a limitation there. We didn't have results of these CD4, CD at a viral load assessments done like the day of or the week before in some patients. So we took three months and we included individuals that had received at least one or more dose of immune checkpoint therapy between January of 2015 to October of 2021, which was our database lock.  And then obviously the regimens included immune checkpoint anti-PD1, PD-L1 monotherapy, or in combination with other anticancer agents including anti-CTLA-4 or chemotherapies targets, which is important to point out here. So the trials that have been mostly done in this space are single-agent checkpoint inhibitors or anti-PD1 with anti-CTLA-4. There's not much data for immune checkpoint inhibition combined with other agents such as targeted therapies, chemotherapies. So we had some of that data in this cohort, which kind of made it interesting. Davide Soldato: Yeah, I think that it's very interesting and it's very wise to choose very broad eligibility criteria for these type of studies because it really answered to the question that we identified and that we spoke about in the beginning.  So going back to the results, you said that the cohort A, so the one that included all the patients, irrespectively of the type of tumor that was diagnosed, it was mainly for evaluating what was the safety of immune checkpoint inhibitors in patients living with HIV and with a concurrent cancer diagnosis. So I was wondering if in this cohort you identified some differences compared to historic data in terms of, for example, incidence of grade three or higher toxicities or incidence of immune-related adverse events in general, and if maybe there was some adverse events that was very characteristic or particular in this cohort. Dr. Abdul Rafeh Naqash: So immune-adverse events is a very interesting question not only from this cohort but in general because it overlaps with this question of autoimmunity and cross T cell cross reactivity. And this is a unique patient population where we have the ability, although not fully but to some extent, to look at the role for CD counts and also look for patterns of adverse events.  To answer your first part of the question, we didn't see any significant differences for the types of adverse events. We did see the incident was a little lower than what you would expect in the real-world setting for non-HIV individuals. Whether that has something to do with how the immune system is constructed in these individuals, nobody knows. We did look at CD4 and CD8 counts. As far as absolute CD4 counts, about 200 or below 200, we didn't see a difference as far as the cumulative incidence for immune checkpoint inhibitor-related adverse events. When we did a ratio of CD4 to CD8 of greater than 0.4 and compared it to less than 0.4, we did see that at around 24 weeks, there was a difference in terms of the cumulative incidence for adverse events. It was around 10% versus 26% when we use that cut-off of 0.4, suggesting that there might be some role of how the peripheral immune system results in the related adverse events in these individuals, but it's a very important question.  I think there are ongoing evaluations that are being done from other prospective studies that had collected blood samples in these individuals. But generally, we saw the same range of adverse events, diarrhea, colitis, pneumonitis, hepatitis. We did have a few patients who had  a history of opportunistic infections, but we didn't see any significant reactivation there which was part of the safety assessment in our analysis.    Davide Soldato: So basically, because I think that in HIV patients, even if those included in the study were almost all were on antiretroviral therapy, but you didn't observe any opportunistic infection that developed during the course of immunotherapy. Dr. Abdul Rafeh Naqash: You're absolutely right, we did not. In fact, we are trying to look at that in a different setting, in a different cohort because there have been some data on mycobacterial reactivation in individuals in general, not just HIV, but in our cohort of 400 odd patients, we did not see any new opportunistic infections. Davide Soldato: I think that one aspect that pops into my mind right now is also that we have kind of some data regarding also possible HPV reactivation in these types of patients treated with immune checkpoint inhibitors. So maybe that could be also something that you would be interested to look at in the future, I imagine.  Dr. Abdul Rafeh Naqash: Yes, we are planning to look at HPV-driven cancers actually for starters, anal and head and neck. We are also looking at hepatitis B-related HCC in a separate ongoing cohort. So there are definitely subsequent steps that we are currently involved in as far as viral-driven cancers and concurrent HIV is concerned. Davide Soldato: Thank you. I think that's very interesting. And I was wondering, you mentioned in the beginning that this patient clearly they have some degree of immune dysregulation or at least some type of dysfunction in terms of immune presentation and immune activation. So I think that one of the concerns or one of the worries of using immune checkpoint inhibitors in this population could also be that the efficacy that we see in patients that do not have HIV could be lower. Could you comment on this if you found any differences both in the cohort including all cancer, but also in the cohort B, that I think you had the strategic idea of pairing these patients living with HIV with patients that were not living with HIV. So I think that this brings very important data to the space. Dr. Abdul Rafeh Naqash: Yes, we tried to look at this one from a tumor-agnostic perspective and a tumor-specific perspective. So the tumor agnostic perspective was looking at a different set of cancers which included skin cancer, melanoma, lung cancer, non-Hodgkin's lymphoma, small cell head and neck, and a couple of other cancers. And one of the things we noticed was that there was a trend, so there was differential efficacy as far as the cancer type is concerned. So for example, skin, Hodgkin's lymphoma, Kaposi sarcoma, melanoma had the highest response rates, somewhere in the range of 60s to 40s. On the other hand, viral-driven cancers such as anal cancer, HCC, head and neck actually had very low response rates, less than 15% or so. So that begs the question of what is going on and we don't necessarily know, which is why we are trying to concentrate on the viral-driven cancers first. Because as you know, melanoma, Kaposi's do have historically shown better responses to checkpoint inhibitors.   Now do we know if when we compare these responses or survival to non-HIV individuals in clinical trials, are the outcomes similar? I would say in some of the tumor types the outcomes were somewhat inferior and in some of the tumor types the outcomes were somewhat similar. So for example, lung, we did compare non-small cell lung cancer. As I mentioned, we had two cohorts, we matched it to a non-HIV cohort and there we looked at progression-free survival and overall survival. And again the caveat is that this is a retrospectively matched cohort, this is not a prospectively matched cohort. So these are individuals that are not matched for each and every variable. They're matched for certain top three or four variables as much as we could accommodate. And based on that we didn't see a difference in the progression-free survival and the overall survival when we did an assessment.  In fact, we looked at it at a 42 month period where we looked at the restricted median survival time and it was not different, was around 17.8% for people with HIV and 18.4% for people without HIV as far as progression-free survival, and around 42% and 41% overall survival at the two-year mark. So basically there is not much significant difference which reiterates the fact that in the right setting, these individuals could be safely treated with immune checkpoint inhibition and could perhaps have similar outcomes. Maybe not in all tumor types, but in some tumor types. But at the end of the day, and we mentioned this in our manuscript also in subsequent work that we are trying to do, we have emphasized on the fact that it has to be a multidisciplinary discussion between the patient, the physician, the medical oncologist, the treating oncologist, and the infectious disease person. Because these individuals have a lot of complicated aspects because of the underlying HIV and taking that into perspective and then assessing risk-benefit is an important discussion.  So the goal of this work was not to establish that immune checkpoint inhibitors are absolutely beneficial or absolutely safe. The goal was more to create awareness that people in the real-world setting actually can benefit, which the next step would be to have more trials and perhaps modify inclusion criteria in clinical trials so that you can have a more inclusive approach, including these individuals.  Davide Soldato: Coming back to the multidisciplinary approach because I think that this is very interesting and should be really implemented when we have this type of patient. From the data that you collected, did you add any indication that maybe this patient treated in the real-world setting were not managed in such a multidisciplinary way? Dr. Abdul Rafeh Naqash: The easiest way to point that out is that most of these people or many of these individuals did not have HIV viral loads or CD4 counts done before treatment initiation. And that's an indirect surrogate for telling you that these are things that should have been thought of, but were not thought of if the individual taking care of these people either did not have expertise as far as HIV is concerned or did not have a colleague on the infectious disease side who was actively managing these people.  So that's an important indirect way where we kind of got a sense that there has to be more awareness about multidisciplinary care. And especially the immune adverse event situation in these individuals can get complicated because of the way their immune system is constructed and having that multidisciplinary care is very important. We didn't specifically collect data on what teams or what subspecialists were involved in each individual's care, but I think that would be an important assessment for maybe a future quality improvement project to look at why or how some of those things were not done so that it can lead to future improvements. Davide Soldato: So, just expanding on that, you said that you didn't have much data in terms of CD4 cells or in terms of viral load. But for what you had inside of your cohort, did you see any modification of these parameters that we know that are very important in patients living with HIV under immune checkpoint inhibitors therapy? Dr. Abdul Rafeh Naqash: Again, a very important immunological question, I think as far as what we saw- so we had close to around 74, 75 individuals that had CD4 T cell counts available. And we didn't see differences between baseline and post-immune checkpoint therapy changes in CD4 counts. Similarly, we didn't see a difference as far as HIV viral load and we had HIV viral loads present in around 107 individuals and we didn't see a difference. Now, again, 30% of our cohort was CD4 count less than 200, and 70% was CD4 count more than 200, , which is again, important to highlight because many trials don't take individuals with the CD4 count less than 200. But in general, we did not see a difference in this pre and post-assessment both for viral load and both for CD4 count. Now trials in this space have ongoing assessments that they are doing. The AIDS Malignancy Consortium does have a trial looking at changes in CD4/CD8 counts or viral loads. In fact, the CITN trial which is a pembrolizumab trial published a couple of years back did have an assessment done as far as CD4 counts and viral loads are concerned. And I think they did see a slight increase in the CD4 counts and there are some aspects about how the immune system may change with an immune checkpoint inhibitor. But I think the strength of the data is not that much, and I think we probably need more patient samples to assess why or how some of that could change or what implications it would have for patients.  Now, there is another concept of HIV viral latency removal that some of the listeners might have heard of, especially in the HIV setting, where you were given an immune checkpoint inhibitor and it can lead to reversal or reduction of the HIV reservoir, which can somehow impact the CD4 counts, and also lead to elimination of the viruses through CD8. But again, that's a more complicated assessment and we didn't have data for it.   Davide Soldato: Thank you very much. That was very interesting also for future perspectives in this topic.  I just wanted to ask you if the idea for the research came more from ensuring equity in terms of care delivery for patients living with HIV or if it was more also to investigate the immunological components that we discussed just as far or a good mix of the two. Dr. Abdul Rafeh Naqash: I think the idea actually stemmed from this individual who's the first author, Dr. Talal El Zarif and co-first author Dr. Amin Nasser from Dana-Farber, reached out a year and a half back and they wanted to look at outcomes from an HIV standpoint and see what the real world setting is. And the goal was they would have their data and we would have our data and we would eventually collect the data together or combine the data together. But then after some conversations, we started looking at the available data, the available literature, saw that there was a decent gap in what we know. And I know there are some brilliant groups in the HIV space, especially at the NCI. In fact, Dr. Kate Lurain and Dr. Ramaswami are good collaborators of ours and they worked in this space and are currently developing trials in this space. But it just did seem like this would be a more interesting approach of answering a real-world question and then also looking at the disparities of it because as an early-phase drug development trialist, I still see a lot of trials, in fact, majority of the trials, say people with HIV or history of HIV are excluded.  Now, the NCI has made important efforts in that space of including those individuals, but I think we still have some ways to go. So basically the idea came from two trainees who were extremely enthusiastic and wanted to pursue this. And I, obviously, seeing their level of enthusiasm and excitement, I was excited too. And then importantly, if you look at the paper, we have a bunch of authors, we have close to 79, 80 authors on that paper. And the primary reason was that each center contributed in certain ways, including patients' data and then expertise. And this ended up being a huge community effort from the oncology community, where everybody's individual effort led to something like this coming to fruition.  So it was a multitude of different aspects, but yes, it all started with a question of how these individuals do and the current data where they're missing gaps, and we wanted to sort of supplement those gaps and provide insights using this important real-world data set. Davide Soldato: Thank you very much for the insight on how the idea came to be.  Is there anything else you would like to add or to summarize for our listeners? Dr. Abdul Rafeh Naqash: Well, first of all, I appreciate the opportunity to discuss our paper here. I would like to thank you and of course the JCO staff for organizing this, and also the JCO Journal for giving us the opportunity to publish this important work. Some of the things that we would like to highlight as outcomes from this paper, as we sort of discussed, but to summarize those: we saw that we didn't have any significant safety concerns, obviously. We saw that some patients in certain tumor types do benefit, similar to what you might expect in a non-HIV setting in the real world as well.  And of course, this was the largest real-world data set of people with HIV and cancer. And we have ongoing efforts in different directions, as I mentioned to you. And we are more than happy to collaborate with anybody who has good ideas because this is a community-level data set. It was created for the community, by the community, and the goal is to utilize this data set. So if there is a listener out there who's interested in collaborating, who has an idea, we're more than happy to share the data set in the right setting. And then hopefully, everybody has the opportunity to lead different efforts in the space. Davide Soldato: Thank you again for being with us today, Dr. Naqash. To hear more from Dr. Naqash, please check out ASCO's JCO Precision Oncology Conversation Podcast.  So this is Davide Soldato. In this episode of JCO Article Insights, we discussed the results of the manuscript titled, “Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer: A Real World Report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International Consortium.” Thank you for your attention and stay tuned for the next episode.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

La curiosa vicenda del soldato statunitense che varca uno dei confini più pericolosi al mondo: quello tra le due Coree Learn more about your ad choices. Visit megaphone.fm/adchoices

Con la partecipazione di Francesca Pellegrini e Maria Vittoria Pierleoni.Guarda il reel.Questa sera parliamo di un altro cult movie per film alla radio: Salvate il soldato Ryan . (Saving Private Ryan) è una pellicola del 1998 diretta da Steven Spielberg, interpretata da Tom Hanks che interpreta John Miller- Presnell nel ruolo del generale Marshall, Matt damon interpreta il soldato Ryan da salvare. La colonna sonora è stata affidata a John Williams, come avere di meglio!Steven Spielberg con questo film vinse il suo secondo premio Oscar per la miglior regia. Il film è ispirato alla vera storia dei Fratelli Niland. La storia è ambientata durante la Seconda guerra mondiale, in particolare nei giorni del D-Day. Di grande interesse sono i primi 24 minuti del film, che dipingono in maniera cruda e realistica lo sbarco dei soldati a Omaha Beach (uno dei nomi in codice dati alla spiaggia della Normandia), particolarmente intensi e apprezzati soprattutto grazie agli effetti sonori (due Oscar a questo reparto).

La storia di Andrei Kravtsov, il soldato russo premiato con un milione di rubli, circa 10.800 euro, per aver distrutto in battaglia un carro armato Leopard di fabbricazione tedesca. I contributi audio di questo episodio sono tratti da (titolo - denominazione canale / canale YouTube - data di pubblicazione): Russian soldier awarded $12,000 for destroying German tank - ShanghaiEye魔都眼 - 21 giu 2023. Iscriviti e segui "Notizie dallUcraina":YouTubeApple PodcastsSpotifyGoogle PodcastsAmazon PodcastAudibleadnkronos.com

Cosa succede se sul treno un soldato russo in fuga dal suo destino di coscritto incontra una donna francese che lo può salvare?Geopolitica e sentimenti si scontrano tra guerra e pace.Maylis de Kerangal, "Fuga a Est", FeltrinelliTimbuctu è un podcast del Post condotto da Marino Sinibaldi. Learn more about your ad choices. Visit megaphone.fm/adchoices

I sopravvissuti al naufragio abbandonati dallo Stato senza letti, riscaldamento, bagni e lenzuola. Le inusuali e preoccupanti dichiarazioni della Cina contro gli Stati Uniti.Scontro tra i cieli di Guidonia tra due aerei militari. Morti entrambi i piloti.L'atroce video dell'esecuzione di un soldato ucraino.Per scriverci: dailyfive@cncmedia.itSeguici su Instagram:@emiliomola1@cnc_mediaDaily Five, ogni giorno dal lunedì al venerdì alle 17:00 con Emilio Mola.Una produzione CNC MediaDirezione creativa e post produzione Likeabee Creative CompanyMusica Giovanni Ursoleo

Benedetta Bini"Il ritorno del soldato"Rebecca WestFazi Editorehtttps://fazieditore.itTraduzione e postfazione di Benedetta BiniIn una casa signorile sulle colline inglesi Kitty e Jenny, come molte connazionali, attendono trepidanti il ritorno di un uomo. Il soldato Chris Baldry, marito di Kitty e cugino di Jenny, si trova «da qualche parte in Francia» a combattere. Nessuna delle due immagina che a varcare la soglia sarà un estraneo, un uomo segnato dalla guerra in maniera indelebile, illeso nel corpo ma dalla psiche martoriata. Insieme al ricordo delle granate e delle membra dilaniate di tanti commilitoni, il trentaseienne Chris ha rimosso gli ultimi quindici anni della propria vita: non rammenta nulla del matrimonio con l'aristocratica Kitty né della tragica perdita del loro figlio, avvenuta poco prima della guerra. I suoi ricordi si fermano alle estati della giovinezza nella casa di famiglia e al primo amore, quello per Margaret, la figlia di un fattore locale. È a lei che scrive annunciando il proprio ritorno imminente e, per un crudele scherzo del destino, è proprio da lei che Kitty e Jenny ricevono la notizia. Le due donne dovranno affrontare una scelta difficile: lasciare che Chris rimanga felicemente inconsapevole della sua vera vita o aiutarlo a richiamare alla memoria i traumi del passato.Il ritorno del soldato, dal quale fu tratto l'omonimo film del 1982, racconta la lotta di un uomo reduce dalla prima guerra mondiale e quella delle due donne che lo amano. Pubblicato per la prima volta nel 1918, l'esordio di Rebecca West, grazie al quale la critica la salutò come una delle scrittrici più promettenti del nuovo secolo, è uno straordinario romanzo sulla guerra e le sue conseguenze nella vita delle persone.Rebecca WestNata Cicely Isabel Fairfield a Londra, prese il suo pseudonimo dall'omonimo personaggio di Ibsen, un'eroina ribelle. Nel corso della sua lunga vita travagliata e romanzesca è stata scrittrice, giornalista, critica letteraria, grande viaggiatrice, femminista ante litteram e politicamente impegnata. La trilogia degli Aubrey, il suo capolavoro, interamente pubblicata da Fazi Editore, è composta da La famiglia Aubrey (2018), Nel cuore della notte (2019) e Rosamund (2019). Fazi Editore ha pubblicato anche i romanzi Quel prodigio di Harriet Hume (2020) e Un matrimonio non premeditato (2021).IL POSTO DELLE PAROLEAscoltare fa Pensarehttps://ilpostodelleparole.itQuesto show fa parte del network Spreaker Prime. Se sei interessato a fare pubblicità in questo podcast, contattaci su https://www.spreaker.com/show/1487855/advertisement

L'incredibile intervento con gli artificieri in sala operatoria.

Il nostro canale Youtube: https://www.youtube.com/channel/UC1vziHBEp0gc9gAhR740fCwSostieni DENTRO LA STORIA su Patreon: https://www.patreon.com/dentrolastoriaAbbonati al canale: https://www.youtube.com/channel/UC1vziHBEp0gc9gAhR740fCw/joinPrima puntata della nostra miniserie dedicata ad Erwin Rommel. Da giovane tenente eroe di Caporetto, decorato con la Pour Le Merite e con la Croce di Ferro di Prima Classe a docente dell'Accademia Militare.Le origini del mito Rommel, la sua formazione militare, i primi successi nella Prima Guerra Mondiale, fino all'avvento del nuovo dittatore tedesco: Adolf Hitler.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/racconti-di-storia-podcast--5561307/support.

Canale Youtube: https://www.youtube.com/channel/UC-Idufifk1hamoBzkZngr1wProduzione, Editing e Sound Design - Matteo D'Alessandro: https://www.instagram.com/unclemattprod/Volete far parte della community e discutere con tanti appassionati come voi? Venite sul nostro gruppo Facebook : https://www.facebook.com/groups/624562554783646/Se volete chiaccherare o giocare con noi, unitevi al server Discord : https://discord.gg/muGgVsXMBWIl nostro Instagram per essere sempre aggiornati sulle novità : https://www.instagram.com/bibliotecadialessandria/?hl=itGruppo Telegram : https://t.me/joinchat/Flt9O0AWYfCUVsqrTAzVcg

A discovery by researchers in Western Australia has identified the earliest known Indigenous man killed in military service. - Una scoperta di ricercatori in Western Australia ha identificato il primo uomo indigeno ucciso mentre prestava servizio militare.

A discovery by researchers in Western Australia has identified the earliest known Indigenous man killed in military service. - Una scoperta di ricercatori in Western Australia ha identificato il primo uomo indigeno ucciso mentre prestava servizio militare.

A discovery by researchers in Western Australia has identified the earliest known Indigenous man killed in military service. - Una scoperta di ricercatori in Western Australia ha identificato il primo uomo indigeno ucciso mentre prestava servizio militare.

Il primo soldato russo processato in Ucraina per un crimine di guerra; l'OMS studia un piano per il vaiolo delle scimmie; un volo per l'emergenza latte in polvere in America. Ascolta la nuova puntata di Actually qui: https://shor.by/ct2g Learn more about your ad choices. Visit megaphone.fm/adchoices

Siamo andati in Cina, dove con la politica Zero Covid di Xi JinpingShanghai è ancora sottoposta a un coprifuoco a zone alterne e a Pechino si impongono nuove, pesanti restrizioni: ne abbiamo parlato con Simone Pieranni, redazione Esteri di il manifesto, autore di "La Cina Nuova", edito da Laterza e con Alessandro Pavannello, produttore musicale che vive a Shanghai, testimone del lockdown. Subito dopo siamo tornati in Ucraina, dove nel 79simo giorno di guerra - mentre continua l'assedio di Azovstal e le forze russe sembrano in stallo nel Donbass - l'inviato del Sole 24Ore Roberto Bongiorni ci ha raccontato le ultime dal campo. Davanti a un tribunale di Kiev è poi iniziato il primo processo contro un soldato russo accusato di crimini di guerra: ne abbiamo parlato con Alessandro Gamberini, avvocato penalista, già docente di diritto penale all'Università di Bologna.

A 28 anni un passato da guerriero guardando all'antica Grecia

Denis, da Bucha, ci racconta come lui e la sua famiglia si siano messi in salvo durante l'occupazione e di come le truppe di Putin abbiano sparso sangue per la propria strada, prima di ritirarsi. Oggi Denis non ha dubbi: l'Ucraina vincerà la guerra voluta da Putin.Intervista a cura di Giovanni Palmisano.#Putin #guerra #Russia #intervista #Bucha

Andrea Frediani"L'ultimo soldato di Mussolini"Newton Compton Editorihttps://www.newtoncompton.com/Un grande romanzoUna guerra senza onoreUna storia impossibile da dimenticareAll'indomani dell'armistizio dell'8 settembre 1943, la vita di Ulisse Savino, un reduce della milizia fascista, è distrutta.Respinto dalla compagna, ignorato dalla stessa figlia, disorientato dalla caduta di Mussolini e del fascismo e pieno di vergogna per il tradimento italiano nei confronti della Germania nazista, non vede vie d'uscita. Ma la creazione della Repubblica di Salò fa rinascere in lui nuove speranze. Unitosi con ritrovato entusiasmo alle file della Legione d'assalto Tagliamento, non vede l'ora di poter affiancare i nazisti nella lotta contro gli Alleati. La realtà che lo attende però è ben diversa e lo porterà a scontrarsi con i partigiani e la popolazione che li sostiene, e a confrontarsi con rastrellamenti, fucilazioni, violenze e soprusi di ogni sorta. Col progredire di questa guerra fratricida, le sue convinzioni cominciano a vacillare; gli eventi di cui è testimone lo spingono a cercare uno scampolo di umanità in un immaginario rapporto con la figlia, e I suoi occhi prendono a guardare in modo diverso coloro che si battono per liberare l'Italia dal giogo del nazifascismo.Un autore da oltre 1 milione di copieUno straordinario romanzo sul periodo più buio della nostra storia«Andrea Frediani accompagna i lettori senza perdersi in luoghi comuni e tenendo fede alla correttezza della ricostruzione storica.»la Repubblica«Frediani sa tenere il pubblico con il fiato sospeso grazie a un ritmo e a una cadenza serrata, tipiche di romanzieri quali Ken Follett, Valerio Massimo Manfredi e Michael Crichton. Il suo stile è fluido, accattivante, mai monotono e ripetitivo, e immerge interamente il lettore nelle vicende narrate e nelle sensazioni provate dai vari personaggi.»Corriere della Sera«Non si può fare a meno di appassionarsi alla narrazione di questo autore.»Il MessaggeroAndrea FredianiÈ nato a Roma nel 1963. Divulgatore storico tra i più noti d'Italia, ha collaborato con numerose riviste specializzate. Con la Newton Compton ha pubblicato diversi saggi e romanzi storici, tra i quali: Jerusalem; Un eroe per l'impero romano; la trilogia Dictator (L'ombra di Cesare, Il nemico di Cesare e Il trionfo di Cesare, quest'ultimo vincitore del Premio Selezione Bancarella 2011); Marathon; La dinastia; 300 guerrieri; 300. Nascita di un impero; I 300 di Roma; Missione impossibile; L'enigma del gesuita. Ha firmato le serie Gli invincibili e Roma Caput Mundi; i thriller storici Il custode dei 99 manoscritti e La spia dei Borgia; Lo chiamavano Gladiatore, con Massimo Lugli; Il cospiratore; La guerra infinita; Il bibliotecario di Auschwitz; I tre cavalieri di Roma e Attacco all'impero, primi volumi della Invasion Saga, I Lupi di Roma, L'ultimo soldato di Mussolini e Le Williams. Le sue opere sono state tradotte in sette lingue. http://andreafrediani.it/IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

Today we speak with Eva Del Soldato about her new book on how the authority of Aristotle was reinscribed and challenged during the early modern period. In his Nicomachean Ethics, Aristotle affirms that despite his friendship with Plato, he was a better friend of the truth. With this statement, he rejected his teacher's authority, implying that the pursuit of philosophy does not entail any such obedience. Yet over the centuries Aristotle himself became the authority par excellence in the Western world, and even notorious anti-Aristotelians such as Galileo Galilei preferred to keep him as a friend rather than to contradict him openly.  In Early Modern Aristotle: On the Making and Unmaking of Authority (University of Pennsylvania Press, 2020), Eva Del Soldato contends that because the authority of Aristotle—like that of any other ancient, including Plato—was a construct, it could be tailored and customized to serve agendas that were often in direct contrast to one another, at times even in open conflict with the very tenets of Peripatetic philosophy. Gerry Milligan is Professor of Italian at the College of Staten Island, where he serves as Director of Honors. He is Professor in Italian and Global Early Modern Studies at the CUNY Graduate Center. His NBN interview is available at here.  Learn more about your ad choices. Visit megaphone.fm/adchoices